<DOC>
	<DOCNO>NCT01144338</DOCNO>
	<brief_summary>This study compare impact include exenatide weekly addition usual care vs. usual care without exenatide major cardiovascular outcome measure primary composite endpoint cardiovascular-related death , nonfatal myocardial infarction ( MI ) , nonfatal stroke .</brief_summary>
	<brief_title>Exenatide Study Cardiovascular Event Lowering Trial ( EXSCEL ) : A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patient type 2 diabetes mellitus Patient HbA1c ≥ 6.5 % ≤ 10.0 % currently use one follow treatment regimen : A ) Treatment 03 oral antihyperglycemic agent B ) Insulin therapy , either alone combination two oral agent Female patient must breast feeding agree use effective method contraception must otherwise risk become pregnant . Patient diagnosis type 1 diabetes mellitus , history ketoacidosis . Patient ever treat approve investigational GLP1 receptor agonist . Patient enrol another experimental protocol involve use investigational drug device , intervention would interfere conduct trial . Patient plan anticipated revascularization procedure . Pregnancy plan pregnancy trial period . Patient endstage renal disease estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2 . Patient history gastroparesis pancreatitis . Personal family history medullary thyroid cancer MEN2 ( Multiple EndocrineNeoplasia Type 2 ) calcitonin level &gt; 40 ng/L baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>exenatide weekly</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>Bydureon</keyword>
	<keyword>Amylin</keyword>
</DOC>